- Home
- LENZ vs PGEN Comparison
LENZ vs PGEN Comparison
Compare LENZ & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LENZ
- PGEN
- Stock Information
- Founded
- LENZ 2019
- PGEN 1998
- Country
- LENZ United States
- PGEN United States
- Employees
- LENZ N/A
- PGEN N/A
- Industry
- LENZ Medicinal Chemicals and Botanical Products
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- LENZ Health Care
- PGEN Health Care
- Exchange
- LENZ Nasdaq
- PGEN Nasdaq
- Market Cap
- LENZ 679.4M
- PGEN 577.0M
- IPO Year
- LENZ 2021
- PGEN N/A
- Fundamental
- Price
- LENZ $23.49
- PGEN $1.91
- Analyst Decision
- LENZ Strong Buy
- PGEN Buy
- Analyst Count
- LENZ 6
- PGEN 5
- Target Price
- LENZ $35.40
- PGEN $7.00
- AVG Volume (30 Days)
- LENZ 98.3K
- PGEN 2.0M
- Earning Date
- LENZ 11-06-2024
- PGEN 03-18-2025
- Dividend Yield
- LENZ 60.66%
- PGEN N/A
- EPS Growth
- LENZ N/A
- PGEN N/A
- EPS
- LENZ N/A
- PGEN N/A
- Revenue
- LENZ N/A
- PGEN $3,963,000.00
- Revenue This Year
- LENZ N/A
- PGEN N/A
- Revenue Next Year
- LENZ N/A
- PGEN $402.12
- P/E Ratio
- LENZ N/A
- PGEN N/A
- Revenue Growth
- LENZ N/A
- PGEN N/A
- 52 Week Low
- LENZ $2.57
- PGEN $0.65
- 52 Week High
- LENZ $38.93
- PGEN $2.17
- Technical
- Relative Strength Index (RSI)
- LENZ 35.48
- PGEN 68.55
- Support Level
- LENZ $24.01
- PGEN $1.63
- Resistance Level
- LENZ $25.90
- PGEN $2.17
- Average True Range (ATR)
- LENZ 1.08
- PGEN 0.18
- MACD
- LENZ 0.02
- PGEN 0.02
- Stochastic Oscillator
- LENZ 9.02
- PGEN 71.74
About LENZ LENZ Therapeutics Inc. Common Stock
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.